Long Term Safety and Efficacy of SC Apomorphine in Treatment of "Off" Episodes in Late-Stage Parkinson's Disease

Phase 3 Completed 800 enrolled Mylan Bertek Pharmaceuticals

Non-randomizedSingle-groupOpen-labelTreatment

Summary

The current protocol is designed to satisfy the need for a compassionate use treatment protocol as well as for a long-term open label follow-up study.

Timeline

Start: 1999-07
Primary completion: —
Completion: 2005-07

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Apomorphine	Unknown	—	Subcutaneous

Long Term Safety and Efficacy of SC Apomorphine in Treatment of "Off" Episodes in Late-Stage Parkinson's Disease

Summary

Timeline

Drugs

Indications